Last reviewed · How we verify
lidocaine and prilocaine
Lidocaine and prilocaine, marketed by Dentsply International, is a local analgesic applied to intact skin. The drug's key strength lies in its well-established market presence, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.
At a glance
| Generic name | lidocaine and prilocaine |
|---|---|
| Also known as | Oraqix periodontal gel |
| Sponsor | Dentsply International |
| Drug class | Amide Local Anesthetic [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Local analgesia on intact skin
- Superficial minor surgery on genital mucous membranes
- Pretreatment for infiltration anesthesia on genital mucous membranes
Common side effects
- Paleness (pallor or blanching)
- Redness (erythema)
- One or more local reactions (intact skin)
- One or more application site reactions (genital mucous membranes)
- Redness (genital mucous membranes)
- Burning sensation (genital mucous membranes)
- Alterations in temperature sensations
- Edema (intact skin)
- Edema (genital mucous membranes)
- Itching
- Rash
- Hyperpigmentation
Serious adverse events
- Anaphylactoid reactions
- Angioedema
- Bronchospasm
- Shock
- Convulsions
- Respiratory depression and arrest
- Cardiovascular collapse
- Unconsciousness
- Bradycardia
- Hypotension
Drug interactions
- Class I antiarrhythmic drugs (e.g., tocainide, mexiletine)
- Nitrates/Nitrites (e.g., nitric oxide, nitroglycerin, nitroprusside, nitrous oxide)
- Local anesthetics (e.g., articaine, benzocaine, bupivacaine, mepivacaine, procaine, ropivacaine, tetracaine)
- Antineoplastic agents (e.g., cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase)
- Antibiotics (e.g., dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides)
- Antimalarials (e.g., chloroquine, primaquine)
- Anticonvulsants (e.g., phenobarbital, phenytoin, sodium valproate)
- Other drugs (e.g., acetaminophen, metoclopramide, quinine, sulfasalazine)
- Class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide)
Key clinical trials
- Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
- Virtual Reality Goggle Utilization for Venipuncture Distraction (NA)
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2, PHASE3)
- The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine (NA)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (PHASE1, PHASE2)
- The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment (PHASE1, PHASE2)
- Comparison of Dural Puncture Epidural and Standard Epidural Anesthesia Techniques in Elective Cesarean Deliveries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lidocaine and prilocaine CI brief — competitive landscape report
- lidocaine and prilocaine updates RSS · CI watch RSS
- Dentsply International portfolio CI